Amgen has announced a deal with the US government that will lower the company’s prescription drug costs for US patients while reinforcing its commitment to US innovation.
As part of the agreement, Amgen’s direct-to-patient programme, AmgenNow, will be expanded to include Aimovig (erenumab) and Amjevita (adalimumab). This will lower the prices of each drug by nearly 60% and 80% respectively compared to the current US list prices. Both drugs will be available at a discounted monthly price of $299.
AmgenNow was launched by the company in October 2025, reducing the price of Repatha (evolocumab) for patients in the US to $239 per month, which is almost 60% below its current US list price.
The programme is open to all eligible patients, including those who are uninsured, patients enrolled in high-deductible health plans or those who choose to pay for prescription drugs with cash or out of pocket.
Amgen has invested over $40bn in R&D and manufacturing in the US over the past seven years.
In 2025, Amgen announced a further $2.5bn investment in US manufacturing capital investments. This included expansions of $900m in Ohio and $1bn in North Carolina.
The agreement means that US pharmaceutical tariffs on the company will be delayed for three years.
Robert A Bradway, chairman and CEO of Amgen, commented: “We look forward to…[seeing] that this biopharmaceutical innovation is appropriately supported globally.”